Nektar Therapeutics

Nektar Therapeutics is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Nektar Therapeutics is not a good value stock. Nektar Therapeutics is not a good growth stock. Nektar Therapeutics is not very popular among insiders. Nektar Therapeutics is a mediocre stock to choose.

Nektar Therapeutics is a biopharmaceutical company, which engages in applying technology platforms t...

News

Acadian Asset Management LLC Reduces Position in Nektar Therapeutics (NASDAQ:NKTR)

Zolmax Acadian Asset Management LLC cut its stake in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 35.5% in the second quarter, according to the company in its most recent filing with the...\n more…

Candriam S.C.A. Takes $99,000 Position in Nektar Therapeutics (NASDAQ:NKTR)

Ticker Report Candriam S.C.A. acquired a new position in Nektar Therapeutics (NASDAQ:NKTR - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities &...\n more…

79,594 Shares in Nektar Therapeutics (NASDAQ:NKTR) Purchased by Candriam S.C.A.

Zolmax Candriam S.C.A. acquired a new stake in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange...\n more…

Why Is Esperion Therapeutics (ESPR) Down 3.9% Since Last Earnings Report?

Zacks Investment Research It has been about a month since the last earnings report for Esperion Therapeutics (ESPR). Shares have lost about 3.9% in that time frame, underperforming the S&P 500.Will the recent negative trend...\n more…

Nektar Therapeutics (NASDAQ:NKTR) Given Consensus Rating of "Hold" by Brokerages

Ticker Report Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) has been given an average rating of "Hold" by the five analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock...\n more…

Nektar Therapeutics' (NASDAQ:NKTR) institutional investors lost 12% over the past week but have profited from longer-term gains

Simply Wall St Key Insights Significantly high institutional ownership implies Nektar Therapeutics' stock price is sensitive to their...\n more…